GEHC
GE HealthCare Technologies Inc.
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- GEHC scores 55.5/100 primarily because its two strongest sub-scores — momentum (14.0) and dividend (13.3) — anchor the total, reflecting genuine quarterly operating improvement and credible free cash flow-backed dividend metrics from SEC filings.
- Financial health at 12.0/20 and profitability at 12.0/20 contribute solid but unexceptional scores, indicating a company that is financially sound without displaying the margin profile or balance sheet efficiency that would push scores into the upper tier.
- The growth sub-score of 10.0/20 reflects only moderate year-over-year improvements in revenue and earnings as recorded in the FY2025 10-K, preventing the composite from reaching the mid-60s or above despite strength in other categories.
Why Not Higher
- The theme sub-score of 0.0/20 is the single largest drag on GEHC's composite score; had the model identified even two qualifying macro-theme exposures, the score would have risen by approximately 5 to 10 points, potentially crossing into a more favorable research tier.
- The growth sub-score of 10.0/20 reflects a filing-derived record of only incremental revenue and earnings gains, and until GEHC demonstrates a sustainably accelerating growth rate in subsequent annual filings, the composite score is unlikely to advance materially.
Data Confidence
9 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
GE HealthCare Technologies Inc. (GEHC) is a global medical technology and digital solutions company spun off from General Electric in January 2023, operating across four primary segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The company develops and manufactures advanced imaging systems (MRI, CT, PET), monitoring equipment, and AI-powered diagnostic software used by hospitals and healthcare providers worldwide. Its scale and installed base position it as one of the largest dedicated medical device and imaging companies globally. The model assigned GEHC a score of 55.5/100, reflecting a mixed but coherent picture across the six scored dimensions. The strongest contributions came from momentum (14.0/20), which captures quarterly improvement in revenues, earnings, and margins from SEC filings — suggesting the business has been on an improving operational trajectory. Dividend (13.3/20) and financial health (12.0/20) also contributed meaningfully, while profitability (12.0/20) and growth (10.0/20) indicate moderate but not exceptional performance. Notably, the theme sub-score is 0.0/20, meaning the model did not identify qualifying macro-theme exposures from the filing data, which materially capped the total score. The core research tradeoff for GEHC is between a company demonstrating genuine operational momentum and reasonable financial health as an independent entity, against a growth profile that has not yet distinguished itself and a complete absence of theme-based tailwind recognition in the model. The best-fit goal profile is dividend income (58.5), marginally ahead of other profiles, suggesting this is a candidate more suited to income-oriented research contexts than aggressive growth mandates.
Plain English
GE HealthCare makes the big medical scanners and monitoring machines you see in hospitals — MRI machines, CT scanners, ultrasound devices — and it was recently spun out of the old General Electric company. A model score of 55.5 out of 100 means the research model sees it as a middle-of-the-road candidate: decent momentum and reasonable dividends, but not standout growth or any major macro-theme tailwinds detected in its filings. The Medium risk rating reflects that it is an established healthcare business but still proving itself as an independent public company with moderate leverage.
Bull Case vs. Bear Case
Bull Case
- The momentum sub-score of 14.0/20 is the highest in the scorecard, indicating that quarterly trends in revenue, earnings, and margins derived from the 10-K filing have been on a measurable upward trajectory, supporting the case for continued operational improvement.
- The dividend sub-score of 13.3/20 reflects meaningful free cash flow coverage of dividends and a credible dividend growth profile, making GEHC a research candidate of interest for income-oriented portfolios despite its relatively recent independence as a public company.
- Financial health scoring 12.0/20 suggests the company maintains a manageable leverage ratio and adequate interest coverage relative to its balance sheet size, providing a degree of resilience that an early-stage spinoff must demonstrate to gain institutional credibility.
Bear Case
- The growth sub-score of only 10.0/20 indicates that year-over-year revenue, net income, and EPS growth rates captured in the SEC filing have been modest, suggesting GEHC has not yet demonstrated the accelerating top- and bottom-line expansion that would justify a higher composite score.
- The theme sub-score of 0.0/20 means the model found no qualifying macro-theme exposures in the filing — such as AI infrastructure, decarbonization, or reshoring — which structurally caps the total score and limits the narrative appeal for thematic or growth-focused research frameworks.
- Profitability at 12.0/20 indicates that net margins, operating margins, and return on assets are adequate but not differentiated, which is a concern for a capital-intensive medical device manufacturer competing against deeply entrenched global peers with superior scale economies.
What Could Change the Picture
Bullish Triggers
- If future 10-K filings show a materially higher growth sub-score — driven by demonstrably accelerating revenue and EPS growth across the Imaging and Pharmaceutical Diagnostics segments — the composite model score would improve and the research case would strengthen.
- Recognition of macro-theme exposures (such as AI-enabled diagnostics, aging demographics infrastructure, or domestic manufacturing initiatives) within the SEC filing language would unlock the theme sub-score from 0.0 and could add meaningful points to the total model score.
Bearish Triggers
- A deterioration in the momentum sub-score in a subsequent filing — caused by decelerating quarterly revenue or compressing operating margins — would remove the primary pillar supporting the current 55.5 score and weaken the research case substantially.
- If leverage ratios were to increase materially or interest coverage were to tighten, reflecting acquisition-driven debt or margin pressure, the financial health sub-score of 12.0/20 could fall, reducing the composite and elevating the risk rating from Medium.
Red Flags
- The theme sub-score of 0.0/20 is a structural ceiling on the model score and reflects an absence of macro-tailwind recognition in the regulatory filings, which could indicate limited strategic positioning language or genuine exposure gaps relative to peers.
- As a 2023 spinoff, GEHC's financial track record as an independent entity is relatively short, and the 10-K data may not yet fully capture normalized debt service costs, stranded-cost elimination timelines, or standalone operating cost structures.
Risk Profile
Medium RiskThe Medium risk rating for GEHC reflects its position as a large, established medical device manufacturer with adequate financial health metrics, tempered by its relatively limited operational history as an independent public company, moderate leverage, and a growth profile that has not yet proven consistent strength across multiple annual filing cycles.
Key Catalysts to Watch
The key factors to watch in future SEC filings are the trajectory of quarterly margin expansion and revenue growth across GEHC's four business segments — particularly Imaging and Pharmaceutical Diagnostics — as well as any evolution in free cash flow generation that could further support or strengthen the dividend sub-score over time.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.